$AKUS News
Last published 3y ago
- 3y agoAKUSGene Therapy Trial for Otoferlin Gene-mediated Hearing Loss - NCT05821959ClinicalTrials.govFrequency of Adverse Events (AEs), Auditory Brainstem Response (ABR) Threshold, Performance of the Akouos Delivery Device
- 3y agoAKUSLLYLilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic DiseasesPR NewswireINDIANAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ:AKUS). The acquisition expands Lilly's efforts in
- 3y agoAKUSLLYLilly and Akouos Announce Expiration of Akouos Tender OfferPR NewswireINDIANAPOLIS and BOSTON, Nov. 30, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Akouos, Inc. (NASDAQ:AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares
- 3y agoAKUSAkouos Reports Third Quarter 2022 Financial Results and Provides Business HighlightsGlobeNewswire-Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on
- 4y agoAKUSLLYLilly to Acquire Akouos to Discover and Develop Treatments for Hearing LossPR NewswireProposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide Transaction valued at approximately $487 million plus a
- 4y agoAKUSOtoferlin Gene-Mediated Hearing Loss Natural History Study - NCT05572073ClinicalTrials.govABR, OAE
- 4y agoAKUSCINCFIXXIONS+1Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM VenturesGlobeNewswireSAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently depl
- 4y agoAKUSAkouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing LossGlobeNewswire-The IND for AK-OTOF is the first to receive FDA clearance for a genetic form of hearing loss and the first for an AAV vector therapy with the potential to treat an inner ear condition -Akouos plans to initiate a pediatric Phase 1/2 clinical trial, in
- 4y agoAKUSAkouos Reports Second Quarter 2022 Financial Results and Provides Business HighlightsGlobeNewswireSubmitted IND for AK-OTOF to FDA Continued progress toward planned IND submission for AK-antiVEGF Presented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF and highlighting strategies for regulated gene expres
- 4y agoAKUSAkouos Reports First Quarter 2022 Financial Results and Provides Business HighlightsGlobeNewswire- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presenting new nonclinical data at ASGCT supporting the planned clinical development of AK-OTOF and highlighting the potential use of m
- 4y agoAKUSAkouos to Present at Bank of America 2022 Healthcare ConferenceGlobeNewswireBOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. ("Akouos") (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Man
- 4y agoAKUSAkouos to Present at the American Society of Gene and Cell Therapy 25th Annual MeetingGlobeNewswireBOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinica
- 4y agoAKUSAkouos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business HighlightsGlobeNewswire- Advanced toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presented data at ARO demonstrating potential of precision genetic medicine platform to address a broad range of inner ear conditions - Expand
- 4y agoAKUSAkouos to Participate in Upcoming March Virtual Investor ConferencesGlobeNewswireBOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. ("Akouos") (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that M
- 4y agoAKUSAkouos Appoints Aaron Tward, M.D., Ph.D., as Chief Scientific OfficerGlobeNewswireBOSTON, March 10, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment o
- 4y agoAKUSAkouos to Present at Cowen 42nd Annual Heath Care ConferenceGlobeNewswireBOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. ("Akouos") (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that M
- 4y agoAKUSAkouos Presents Nonclinical Data Demonstrating Potential Applicability of Precision Genetic Medicine Platform for a Broad Range of Inner Ear Conditions at the Association for Research in Otolaryngology 45th Annual Mid-Winter MeetingGlobeNewswire- Data from two nonclinical studies evaluating protein expression and tolerability support future clinical development of AK-antiVEGF for the treatment of vestibular schwannoma - AAVAnc80 and a supporting cell selective promoter can drive widespread G
- 4y agoAKUSAkouos to Participate in Upcoming February Virtual Investor ConferencesGlobeNewswireBOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. ("Akouos") (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that me
- 4y agoAKUSAkouos to Present at the Association for Research in Otolaryngology 45th Annual Mid-Winter MeetingGlobeNewswireBOSTON, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinic
- 4y agoAKUSAkouos to Present at Piper Sandler 33rd Annual Virtual Healthcare ConferenceGlobeNewswireBOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. ("Akouos") (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Ma
- 5y agoAKUSAkouos Reports Third Quarter 2021 Financial Results and Provides Business HighlightsGlobeNewswire- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Expanded leadership team with appointment of Stacy Price as chief technical officer BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Akou
- 5y agoAKUSAkouos Appoints Stacy Price as Chief Technical OfficerGlobeNewswireBOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of
- 5y agoAKUSAkouos to Present at Jefferies Gene Therapy/Editing SummitGlobeNewswireBOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. ("Akouos") (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Ma
- 5y agoAKUSAkouos to Present at Upcoming September Virtual Investor ConferencesGlobeNewswireBOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. ("Akouos") (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that M
- 5y agoAKUSAkouos Reports Second Quarter 2021 Financial Results and Provides Business HighlightsGlobeNewswire- Announced European Commission designation of AK-OTOF as an orphan drug for the treatment of otoferlin gene-mediated hearing loss - Advanced both AK-OTOF and AK-antiVEGF towards planned IND submissions in the first half of 2022 and in 2022, respectiv
- 5y agoAKUSAkouos Announces European Commission Designation of AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss as an Orphan DrugGlobeNewswireBOSTON, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that the European
- 5y agoAKUSAkouos Reports First Quarter 2021 Financial Results and Provides Business UpdatesGlobeNewswire- Leadership team expanded with appointment of Kathy Reape, M.D. as chief development officer - AK-OTOF granted both Orphan Drug Designation and Rare Pediatric Disease Designation by FDA and is on track for planned IND submission in first half of 20
- 5y agoAKUSAkouos Presents Nonclinical Data Supporting Future Clinical Development of AK-OTOF and AK-antiVEGF at the American Society of Gene and Cell Therapy 24th Annual MeetingGlobeNewswire- Intracochlear delivery of a dual AAVAnc80 vector encoding human otoferlin results in full-length protein expression in inner hair cells of non-human primates and in durable protein expression sufficient for sustained restoration of auditory function in
- 5y agoAKUSAkouos to Present at Bank of America 2021 Virtual Healthcare ConferenceGlobeNewswireBOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. ("Akouos") (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Man
- 5y agoAKUSAkouos Appoints Dr. Kathy Reape as Chief Development OfficerGlobeNewswireBOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of
- 5y agoAKUSAkouos to Present Nonclinical Data from AK-OTOF and AK-antiVEGF Programs at the American Society of Gene and Cell Therapy 24th Annual MeetingGlobeNewswireBOSTON, April 27, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclini
- 5y agoAKUSAkouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing LossGlobeNewswireBOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...
- 5y agoAKUSAkouos to Present at 20th Annual Needham Virtual Healthcare ConferenceGlobeNewswireBOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
- 5y agoAKUSAkouos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business HighlightsGlobeNewswire- In 2020, continued to advance genetic medicine pipeline with execution of IND-enabling studies for AK-OTOF and general alignment with FDA on the path to a 2022 IND submission for AK-antiVEGF -...
- 5y agoAKUSAkouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory NeuropathyGlobeNewswireThe Resonate™ program provides access to a potential genetic diagnosis by offering genetic testing at no cost to eligible individuals, their insurance, or their healthcare providersA genetic diagnosis...
- 5y agoAKUSAkouos to Present at Piper Sandler 32nd Annual Virtual Healthcare ConferenceGlobeNewswireBOSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
- 6y agoAKUSAkouos Reports Third Quarter 2020 Financial Results and Provides Business HighlightsGlobeNewswire- Expanded leadership team with appointment of Sachiyo Minegishi as CFO and promotion of Jennifer Wellman to COO - - Continued progress towards 2021 IND submission for AK-OTOF, a gene therapy...
- 6y agoAKUSAkouos Announces Key Leadership AppointmentsGlobeNewswireBOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...
- 6y agoAKUSAkouos to Present at Upcoming October Virtual Investor ConferencesGlobeNewswireBOSTON, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...
- 6y agoAKUSAkouos to Present at Cantor Global Virtual Healthcare ConferenceGlobeNewswireBOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
- 6y agoAKUSAkouos Reports Second Quarter 2020 Financial Results and Provides Business HighlightsGlobeNewswire- Upsized IPO in June 2020 raised $244.4 million in gross proceeds - - Company plans to advance lead product candidate, AK-OTOF, for the treatment of hearing loss due to mutations in the OTOF...
- 6y agoAKUSAkouos Announces Expansion of Executive Team and Board of DirectorsGlobeNewswireAlan Smith, Ph.D., Joins as Chief Technology Officer Saira Ramasastry Joins Board of Directors; Arthur Tzianabos, Ph.D., Role Expanded to Chairman BOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Akouos,...
- 6y agoAKUSAkouos to Present at BTIG Virtual Biotechnology ConferenceGlobeNewswireBOSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for people worldwide who live...
- 6y agoAKUSAkouos Announces Pricing of Initial Public OfferingGlobeNewswireBOSTON, June 25, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve,...